<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792866</url>
  </required_header>
  <id_info>
    <org_study_id>CE_20200204_1_ALR</org_study_id>
    <nct_id>NCT04792866</nct_id>
  </id_info>
  <brief_title>3D FLAIR Versus Coronal T2-WI MRI in Detecting Optic Neuritis (FLACON)</brief_title>
  <acronym>FLACON</acronym>
  <official_title>3D FLAIR Versus Coronal T2-WI MRI in Detecting Optic Neuritis in Patients Presenting With Acute Visual Loss and Otherwise Normal Ophthalmological Examination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      3D FLAIR, 3D T1 FAT SAT, coronal T2 and coronal T1 dixon sequences were usually used to&#xD;
      assess visual deficits in MRI. Optic nerve examination is preferably performed using a&#xD;
      coronal T2 sequence in order to detect a hypersignal suggestive of inflammation whereas brain&#xD;
      examination is preferably performed using a 3D FLAIR sequence to highlight signs of spatial&#xD;
      dissemination and lesions suggestive of multiple slerosis (MS).&#xD;
&#xD;
      Recently, a study based on a small number of patients showed the interest of 3D FLAIR in the&#xD;
      detection of the hypersignal of the optic nerve.The objective of this retrospective study is&#xD;
      to determine whether a single 3D FLAIR sequence allows simultaneous exploration of the optic&#xD;
      nerve and the brain for the positive diagnosis of optic neuropathy and/or MS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">August 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of optic neuropathies using MRI</measure>
    <time_frame>1 hour</time_frame>
    <description>MRI comparison of the diagnostic performance of the 3D FLAIR sequence and the T2 coronal in the detection of optic neuropathies.</description>
  </primary_outcome>
  <enrollment type="Actual">1200</enrollment>
  <condition>Optic Neuritis</condition>
  <condition>Multiple Sclerosis</condition>
  <condition>Encephalopathy</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Comparing 3D FLAIR versus Coronal T2-WI MRI in detecting Optic Neuritis</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting with acute visual loss and explored by MRI&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Decrease in visual acuity explored in MRI between january 2018 and january 2020&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past history of episode of Optic neuritis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>HÃ´pital Fondation Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Optic Neuritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

